Olema Pharmaceuticals(OLMA)
$7.06-0.16 (-2.22%)
OLMA
Olema Pharmaceuticals financials statements
$7.06
At close:-0.16 (-2.22%)
Want to see OLMA full AI Analyst Report?
Olema Pharmaceuticals (OLMA) Ratios
1,020 Followers
Olema Pharmaceuticals Ratios
OLMA's free cash flow for Q3 2026 was $-48.01M. For the 2026 fiscal year, OLMA's free cash flow was decreased by $-900.00K and operating cash flow was $-47.11M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.95 | 10.50 | 12.33 | 12.62 | 32.23 |
| Quick Ratio | 9.95 | 10.50 | 12.33 | 12.62 | 32.23 |
| Cash Ratio | 0.93 | 3.34 | 3.17 | 1.43 | 1.53 |
| Solvency Ratio | -2.95 | -3.07 | -4.18 | -5.77 | -6.23 |
| Operating Cash Flow Ratio | -2.83 | -2.50 | -3.87 | -4.96 | -5.62 |
| Short-Term Operating Cash Flow Coverage | -130.53 | -89.04 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 460.58M | $ 396.46M | $ 243.46M | $ 190.80M | $ 279.31M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.11 | 1.10 | 1.09 | 1.09 | 1.04 |
| Debt Service Coverage Ratio | -144.09 | -110.14 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.02 | 0.05 | 0.06 | 0.08 |
| Net Debt to EBITDA | 0.29 | 1.07 | 0.63 | 0.20 | 0.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 90.91% | 91.01% | 92.09% | 97.94% | 99.45% |
| Return on Assets (ROA) | -30.45% | -28.71% | -34.90% | -48.59% | -24.02% |
| Return on Equity (ROE) | -33.95% | -31.66% | -38.07% | -53.04% | -24.98% |
| Return on Capital Employed (ROCE) | -37.10% | -34.76% | -41.11% | -53.74% | -24.92% |
| Return on Invested Capital (ROIC) | -37.02% | -34.66% | -40.95% | -53.46% | -24.84% |
| Return on Tangible Assets | -30.45% | -28.75% | -34.90% | -48.59% | -24.02% |
| Earnings Yield | -7.47% | -37.81% | -15.23% | -106.94% | -19.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.69 | -1.78 | -1.85 | -2.05 | -1.28 |
| Free Cash Flow Per Share | -1.69 | -1.78 | -1.85 | -2.06 | -1.32 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -656.30 | 0.00 | -226.07 | -32.18 |
| Capital Expenditure Coverage Ratio | 0.00 | -656.30 | 0.00 | -226.07 | -32.18 |
| Operating Cash Flow Coverage Ratio | -122.98 | -73.02 | -34.64 | -31.99 | -15.41 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -6.75% | -30.52% | -13.19% | -84.12% | -14.13% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.37 | -2.65 | -6.57 | -0.94 | -5.20 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.55 | 0.84 | 2.50 | 0.50 | 1.30 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -14.83 | -3.28 | -7.58 | -1.19 | -7.08 |
| Price-to-Operating Cash Flow Ratio | -14.83 | -3.28 | -7.58 | -1.19 | -7.30 |
| Price-to-Earnings Growth (PEG) Ratio | 0.89 | -0.95 | 0.36 | -0.02 | -0.02 |
| Enterprise Value Multiple | -13.14 | -1.58 | -5.44 | -0.72 | -5.04 |
| Enterprise Value | 2.13B | 204.42M | 568.69M | 76.85M | 359.42M |
| EV to EBITDA | -13.14 | -1.58 | -5.44 | -0.72 | -5.04 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -14.50 | -1.96 | -6.79 | -0.93 | -6.88 |
| EV to Operating Cash Flow | -14.50 | -1.96 | -6.79 | -0.94 | -7.09 |
| Tangible Book Value Per Share | 5.50 | 6.95 | 5.61 | 4.94 | 7.20 |
| Shareholders’ Equity Per Share | 5.50 | 6.96 | 5.61 | 4.94 | 7.20 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.87 | -2.20 | -2.14 | -2.62 | -1.80 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.92 | 0.98 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.90 | 0.81 | 0.87 | 0.78 | 0.71 |
Currency in USD

